SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings.
Guggenheim Securities Healthcare Innovation Conference (November 11 – 13, 2024)
Location: InterContinental Hotel, Boston, MA
Format: Fireside Chat
Date and Time: Tuesday, November 12, 2:00 pm Eastern Time
Jefferies London Healthcare Conference (November 19 – 21, 2024)
Location: The Waldorf Hilton, London, UK
Format: Presentation
Date and Time: Wednesday, November 20, 12:30 pm Greenwich Mean Time
7th Annual Evercore HealthCONx Conference (December 3 – 5, 2024)
Location: Loews Coral Gables Hotel, Coral Gables, FL
Format: Fireside Chat
Date and Time: Wednesday, December 4, 11:15 am Eastern Time
A live audio webcast of the events will be available online at Erasca.com/events. An archived replay of the events will be available for 90 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.75 |
| Daily Volume: | 573,688 |
| Market Cap: | US$777.510M |
November 12, 2024 September 25, 2024 August 29, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
